New hope for tough leukemia: targeted drug BL-M11D1 enters human testing
NCT ID NCT06714591
First seen Oct 31, 2025 · Last updated Jun 21, 2026 · Updated 35 times
Summary
This early-phase trial is testing a new drug called BL-M11D1 in 120 adults with acute myeloid leukemia that has returned or not responded to standard treatments. The drug is designed to target and kill leukemia cells while sparing healthy ones. The main goals are to check safety, find the right dose, and get an early look at whether it can shrink or control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
Contact
Contact Email: •••••@•••••
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
Contact
Contact Email: •••••@•••••
-
John Theurer Cancer Center-Hackensack
RECRUITINGHackensack, New Jersey, 07601, United States
Contact
Contact Email: •••••@•••••
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Email: •••••@•••••
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact Email: •••••@•••••
-
Northwestern Memorial Hospital
RECRUITINGChicago, Illinois, 60611, United States
Contact
Contact Email: •••••@•••••
-
Oncology Hematology Care Clinical Trials, LLC
RECRUITINGCincinnati, Ohio, 45236, United States
Contact Email: •••••@•••••
Contact
-
Oregon Health and Science University
RECRUITINGPortland, Oregon, 97239, United States
Contact Email: •••••@•••••
Contact
-
SCRI -TriStar BMT
RECRUITINGNashville, Tennessee, 37203, United States
Contact Email: •••••@•••••
Contact
-
START Midwest/The Cancer and Hematology Center
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Temple Health Fox Chase Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19111, United States
Contact Email: •••••@•••••
Contact
-
The Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Email: •••••@•••••
Contact
-
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RECRUITINGBaltimore, Maryland, 21287, United States
Contact
Contact Email: •••••@•••••
-
UCLA Ronald Reagan Medical Center
RECRUITINGLos Angeles, California, 90095, United States
Contact Email: •••••@•••••
Contact
-
University of Colorado Anschutz Medical Campus
RECRUITINGAurora, Colorado, 80045, United States
Contact
Contact Email: •••••@•••••
-
Virginia Cancer Specialists
RECRUITINGFairfax, Virginia, 22031, United States
Contact Email: •••••@•••••
Contact
-
WVCI Oncology Associates of Oregon
RECRUITINGEugene, Oregon, 24224, United States
Contact Email: •••••@•••••
Contact
-
Yale Cancer Center, Smilow Cancer Hospital at Yale New Haven
RECRUITINGNew Haven, Connecticut, 06511, United States
Contact
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL-M11D1 (a targeted drug that delivers a toxin to leukemia cells)
What this could lead to
If it works, this could point toward a new treatment option for people with acute myeloid leukemia that has come back or not responded to standard therapy.
What could go wrong
This is a very early Phase 1 trial with only 120 participants, so the drug may not prove safe or effective. Side effects could be severe, including low blood counts and organ damage.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.